5 Common Medications That Can Trigger Atrial Fibrillation
Atrial fibrillation (AF or afib) is the most common sustained cardiac arrhythmia encountered in clinical practice, and while underlying heart disease and age are primary drivers, medications can play a meaningful role in triggering new or recurrent episodes. Understanding which commonly prescribed and over-the-counter drugs are associated with atrial fibrillation helps patients and clinicians weigh benefits and risks, tailor monitoring plans, and consider alternatives when appropriate. This article reviews five categories of medications that have been linked to AF, explains likely mechanisms, and outlines practical steps for reducing risk while emphasizing the importance of individualized medical advice.
Which widely used drugs raise the risk of atrial fibrillation?
Several drug classes are repeatedly implicated in observational studies and clinical reports of atrial fibrillation. These include sympathomimetics (found in bronchodilators and decongestants), central nervous system stimulants, thyroid hormone preparations when overdosed, certain anti-inflammatory agents, and some cancer-targeted therapies. The common thread is that these medications can increase heart rate, alter autonomic balance, change electrolyte handling, or provoke cardiac inflammation and structural stress—each of which can create a substrate for AF. Risk is generally higher in people with preexisting cardiovascular disease, older adults, those with uncontrolled thyroid disease, and patients taking multiple interacting drugs.
Bronchodilators and decongestants: albuterol, salbutamol and pseudoephedrine
Short-acting beta-agonist bronchodilators such as albuterol (salbutamol) are cornerstone therapies for COPD and asthma but have known cardiovascular effects including tachycardia and palpitations. By stimulating beta-adrenergic receptors, these drugs increase sympathetic tone and can precipitate arrhythmias in susceptible people. Over-the-counter nasal decongestants like pseudoephedrine and phenylephrine are sympathomimetics with similar effects on heart rate and blood pressure; they have been associated with incident atrial fibrillation in case reports and observational analyses. For most patients the therapeutic benefit outweighs the risk, but clinicians often recommend caution or alternative agents for older adults or anyone with a history of AF or significant heart disease.
Stimulant medications and sympathomimetics: ADHD drugs and appetite suppressants
Central nervous system stimulants such as amphetamine salts and methylphenidate, prescribed for attention-deficit/hyperactivity disorder (ADHD), increase catecholamine signaling and can elevate heart rate and blood pressure. In clinical practice and pharmacovigilance data, stimulants have been linked to new-onset arrhythmias, including atrial fibrillation, especially in adults with underlying cardiac risk factors. Appetite suppressants and recreational stimulants carry similar concerns. Monitoring strategies—baseline cardiac history, blood pressure checks, and symptom-driven ECG assessment—are typically recommended. Shared decision-making should balance symptomatic benefits against arrhythmia risk, with dose adjustments or non-stimulant alternatives considered where appropriate.
Thyroid hormone replacement: levothyroxine and the risk of over-replacement
Thyroid hormone status has a well-established relationship with atrial fibrillation: overt hyperthyroidism is a classic reversible cause of AF. Levothyroxine replacement is a common and generally safe therapy for hypothyroidism, but excessive dosing that leads to iatrogenic thyrotoxicosis can increase the risk of AF by heightening metabolic rate, increasing adrenergic sensitivity, and promoting structural remodeling of the atria. Regular laboratory monitoring of thyroid-stimulating hormone (TSH) and attention to symptoms—palpitations, unexplained weight loss, or tremor—help prevent over-replacement. In older patients or those with cardiac disease, clinicians often aim for more conservative thyroid targets to minimize arrhythmia risk.
Anti-inflammatory and immunosuppressive drugs: NSAIDs and corticosteroids
Nonsteroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids are commonly used for pain, inflammation, and a range of medical conditions. Several observational studies have identified a modest association between NSAID use and incident atrial fibrillation, potentially related to fluid retention, blood pressure elevation, or direct effects on atrial electrophysiology. High-dose systemic corticosteroids have also been reported to precipitate AF, possibly through electrolyte shifts, increased catecholamines, or pro-arrhythmic changes in myocardial excitability. These associations do not imply that these agents are unsafe for everyone, but they do support cautious use among patients with existing AF risk factors and consideration of the lowest effective dose for the shortest duration necessary.
Cancer therapies and targeted agents: ibrutinib and selected chemotherapies
Some modern cancer therapies carry a recognized risk of atrial fibrillation. Ibrutinib, a Bruton’s tyrosine kinase inhibitor used in certain hematologic malignancies, has been repeatedly associated with an increased incidence of AF in clinical trials and postmarketing reports. The mechanism may involve off-target effects on cardiac signaling pathways and atrial remodeling. Other chemotherapeutic agents and targeted therapies can also influence cardiac rhythm through direct cardiotoxicity, inflammation, or changes in autonomic balance. For patients on such treatments, oncology and cardiology teams often collaborate to monitor rhythm, manage anticoagulation when AF occurs, and consider therapy modification if arrhythmias become problematic.
| Medication class | Common examples | How it may trigger AF | Clinical considerations |
|---|---|---|---|
| Beta-agonists & decongestants | Albuterol, pseudoephedrine | Increased sympathetic tone, tachycardia | Use cautiously in older adults or with heart disease |
| Stimulants | Amphetamines, methylphenidate | Catecholamine-mediated arrhythmia risk | Baseline CV assessment, monitor symptoms |
| Thyroid hormone | Levothyroxine | Thyrotoxicosis increases AF risk | Regular TSH monitoring; avoid over-replacement |
| Anti-inflammatory agents | Ibuprofen, prednisone (systemic) | Fluid retention, BP changes, electrolyte shifts | Lowest effective dose; monitor in high-risk patients |
| Cancer-targeted therapies | Ibrutinib, some TKIs/chemotherapies | Direct cardiotoxic or off-target signaling effects | Cardio-oncology coordination for monitoring |
Reducing medication-related atrial fibrillation risk
Mitigating the risk of drug-induced AF focuses on identifying individual risk factors, reviewing the full medication list (including over-the-counter products and supplements), and selecting alternatives when possible. For people at elevated cardiac risk, clinicians may prefer non-stimulant options for ADHD, limit use of systemic sympathomimetics, aim for conservative thyroid replacement targets, and use the lowest effective doses of NSAIDs or steroids. If a medication suspected of precipitating AF is necessary, closer monitoring—periodic ECGs, ambulatory rhythm monitoring for symptoms, and collaboration between specialists—helps detect arrhythmia early. Shared decision-making is essential; do not stop prescription medications without consulting your healthcare provider.
While many commonly used drugs can increase the chance of atrial fibrillation in susceptible people, the absolute risk depends on age, baseline heart health, concurrent therapies, and dosing. If you have concerns about a specific medication on your list—prescription or over-the-counter—discuss them with your clinician to weigh alternatives and monitoring plans tailored to your situation. This article provides general information and is not a substitute for professional medical advice. If you have new palpitations, fainting, chest pain, or shortness of breath, seek prompt medical evaluation.
Disclaimer: This article is informational and not a substitute for professional medical advice. For personalized guidance about medications and atrial fibrillation risk, consult your healthcare provider or a cardiologist.
This text was generated using a large language model, and select text has been reviewed and moderated for purposes such as readability.
